Trivitron buys Ani Labsystems for €15.8 mln
Trivitron Healthcare Private Limited has acquired Finnish diagnostics technology company Ani Labsystems for €15.8 million (Rs 110 crore).
With this acquisition, Trivitron enters into the Point of Care Diagnostics, Immuno Diagnostics and Molecular Diagnostics. These three areas are the fastest growing in the in vitro diagnostics field.
The Finnish diagnostics technology company is a group of companies including Ani Biotech, Ani Labsystems, Biopoint and K3. Trivitron has bought all these companies and will merge them into Labsystems Diagnostics OY, a Trvitron group company.
Ani Labsystems specializes in manufacturing of neonatal screening, cardiac, gastro, respiratory diagnostic kits and infectious disease testing products.
This acquisition will make Trivitron a global in vitro diagnostic company with the ability to manufacture variety of diagnostic kits covering all major areas of in vitro diagnostics field.
Trivitron Healthcare has also formed 49:51 JV with Italy-based DiaSorin Group to enter the immuno diagnostics market. The joint venture will be called DiaSorin Trivitron Healthcare Pvt Ltd which will cater to the Indian InVitro Diagnostics market of around $500 million and Indian immunodiagnostic market of around $165 million.
The company also raised around Rs 400 crore in a round led by Fidelity Growth Partners India which will be used to partially finance the acquisitions and to increase Trivitron’s shareholding in Kiran Medical Systems.
In this segment, Transasia Bio-Medical bought French company Maxmat SA, that specializes in conception, design, development and manufacturing of automated analyzers and reagents in the field of clinical chemistry, hemostatis and immunology. Also, American AB Sciex bought mass spectrometry business of LabIndia Instruments.
Trivitron is a global medical technology company focusing on manufacturing, innovation, distribution and after sales support. The company through its innovations and collaborative initiatives makes healthcare affordable and accessible to the emerging markets.
